Intrust Bank’s Exagen XGN Stock Holding History

Intrust Bank’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,031	Closed	-$57K	–	393
2022 Q2	$57K	Buy	+10,031	New	+$58.4K	0.01%	383

Other funds holding XGN

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Intrust Bank's XGN Position: Q3 2022 in Review

Intrust Bank sold out of Exagen (XGN) in Q3 2022, closing a stake of 10,031 shares — an estimated $57K sold.

Intrust Bank first reported a position in XGN in Q2 2022 and held it in 1 quarter. The position peaked at $57K in Q2 2022. 38 funds tracked by Wall St. Rank hold XGN as of Q3 2022.

Intrust Bank reported no remaining Exagen position as of Q3 2022 after selling out during the quarter.
Intrust Bank sold 10,031 Exagen shares in Q3 2022, an estimated $57K.
Intrust Bank first reported a position in Exagen in Q2 2022 and held it in 1 quarter.
Intrust Bank's Exagen position peaked at $57K in Q2 2022.
38 funds tracked by Wall St. Rank held Exagen as of Q3 2022.

Based on Intrust Bank's 13F filing for Q3 2022, filed 9 Nov 2022.